{"id":505151,"date":"2020-09-02T14:22:02","date_gmt":"2020-09-02T14:22:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=505151"},"modified":"2020-09-02T14:22:02","modified_gmt":"2020-09-02T14:22:02","slug":"diffuse-large-bcell-lymphoma-emerging-drugs-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diffuse-large-bcell-lymphoma-emerging-drugs-2020_505151.html","title":{"rendered":"Diffuse Large B-Cell Lymphoma Emerging Drugs, 2020"},"content":{"rendered":"
\"Diffuse<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
Diffuse Large B-cell Lymphoma Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diffuse Large B-cell Lymphoma market. A detailed picture of the Diffuse Large B-cell Lymphoma pipeline landscape is provided, which includes the disease overview and Diffuse Large B-cell Lymphoma treatment guidelines. <\/div>\n

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center and post germinal center B-cells.<\/p>\n

 <\/p>\n

Diffuse Large B-Cell Lymphoma Emerging Drugs<\/a><\/strong><\/p>\n

    \n
  1. Lisocabtagene maraleucel: Bristol-Myers Squibb<\/li>\n
  2. Brentuximab Vedotin: Seattle Genetics\/Takeda<\/li>\n
  3. Loncastuximab Tesirine: ADC Therapeutics<\/li>\n
  4. Tafasitamab: Morphosys\/Incyte<\/li>\n
  5. Treakisym: SymBio Pharmaceuticals<\/li>\n
  6. Enzastaurin (DB102): Denovo Biopharma<\/li>\n
  7. Ublituximab + Umbralisib: TG Therapeutics<\/li>\n
  8. Blinatumomab: Amgen<\/li>\n
  9. Aliqopa (Copanlisib\/BAY 80-6946): Bayer<\/li>\n
  10. Imbruvica (Ibrutinib): Janssen\/Pharmacyclics (AbbVie Company)<\/li>\n
  11. Odronextamab (REGN1979): Regeneron Pharmaceuticals<\/li>\n
  12. Imfinzi (durvalumab): Celgene\/Bristol Myers Squibb<\/li>\n
  13. Parsaclisib (INCB050465): Incyte Corporation<\/li>\n
  14. TC 110: TCR2 Therapeutics<\/li>\n
  15. DPX-Survivac: IMV, inc. & Merck<\/li>\n
  16. Acalabrutinib: AstraZeneca<\/li>\n
  17. AUTO3: Autolus Therapeutics<\/li>\n
  18. Obinutuzumab: Hoffmann-La Roche<\/li>\n
  19. CLR 131: Cellectar Bioscience<\/li>\n
  20. Debio1562: Debiopharm International<\/li>\n<\/ol>\n

     <\/p>\n

    The dynamics of the DLBCL therapeutic market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as MorphoSys, Cellectar, ADC Therapeutics, and others are involved in developing drugs for DLBCL.<\/strong><\/a><\/p>\n

    MOR208 (MorphoSys) also known as Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19, which is assumed to be involved in B cell receptor (BCR) signaling. MorphoSys is clinically investigating MOR208 as a therapeutic option in B cell malignancies in several combination trials. The MOR208 in combination with lenalidomide; bendamustine is being investigated individually in patients with relapsed\/refractory DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) in the phase II\/III trial. Based on interim data from L-MIND study, the FDA granted Breakthrough Therapy Designation for MOR208 plus lenalidomide in this patient population. Along with this, Orphan drug designation was received for MOR208 for the indications of DLBCL and CLL\/SLL from FDA and EMA.<\/p>\n

    ADCT-402 (ADC Therapeutics) also known as loncastuximab tesirine is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine (PBD)-dimer toxin. CD19 is an ideal target for an ADC approach, as it is highly expressed in a range of B-cell hematological tumors, including certain types of lymphoma and leukemia. Once bound to a CD19-expressing cell, it internalized into the cell where enzymes release the PBD-based warhead. The FDA has granted orphan drug designation to ADCT-402 for the treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The ADC Therapeutics is currently conducting Phase II clinical trial in patients with relapsed or refractory (R\/R), Phase I trial in combination with ibrutinib; and durvalumab in patients with R\/R DLBCL or follicular lymphoma and melanoma.<\/p>\n

    Selinexor (Karyopharm Therapeutics) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound and functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. The FDA granted Fast Track designation to Selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies and are not eligible for high dose chemotherapy with stem cell rescue or CAR-T therapy. FDA has granted Selinexor orphan designation for both multiple myeloma and DLBCL.<\/p>\n

    CLR 131 (Cellectar) is a small-molecule, targeted Phospholipid Drug Conjugate (PDC) designed to deliver cytotoxic radiation directly and selectively to cancer cells. It is a lead therapeutic PDC product candidate of Cellectar. Currently, company is conducting the Phase II trial for the treatment of Diffuse Large B Cell Lymphoma and other indications such as Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and others. <\/p>\n

    Scope of the report<\/span><\/a><\/h2>\n